141 related articles for article (PubMed ID: 15341941)
1. Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
Heath JA; Mehrotra MM; Chi S; Yu JC; Hutchaleelaha A; Hollenbach SJ; Giese NA; Scarborough RM; Pandey A
Bioorg Med Chem Lett; 2004 Oct; 14(19):4867-72. PubMed ID: 15341941
[TBL] [Abstract][Full Text] [Related]
2. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.
Furuta T; Sakai T; Senga T; Osawa T; Kubo K; Shimizu T; Suzuki R; Yoshino T; Endo M; Miwa A
J Med Chem; 2006 Apr; 49(7):2186-92. PubMed ID: 16570914
[TBL] [Abstract][Full Text] [Related]
3. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Ushiki J; Seishi T; Ichimura M; Giese NA; Yu JC; Takahashi S; Oda S; Nomoto Y
J Med Chem; 2003 Nov; 46(23):4910-25. PubMed ID: 14584942
[TBL] [Abstract][Full Text] [Related]
4. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Pandey A; Volkots DL; Seroogy JM; Rose JW; Yu JC; Lambing JL; Hutchaleelaha A; Hollenbach SJ; Abe K; Giese NA; Scarborough RM
J Med Chem; 2002 Aug; 45(17):3772-93. PubMed ID: 12166950
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Nakajima T; Ichimura M; Giese NA; Yu JC; Lokker NA; Ushiki J; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Sep; 45(20):4513-23. PubMed ID: 12238930
[TBL] [Abstract][Full Text] [Related]
6. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Matsuno K; Seishi T; Nakajima T; Ichimura M; Giese NA; Yu JC; Oda S; Nomoto Y
Bioorg Med Chem Lett; 2003 Sep; 13(18):3001-4. PubMed ID: 12941321
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.
Matsuno K; Ichimura M; Nakajima T; Tahara K; Fujiwara S; Kase H; Ushiki J; Giese NA; Pandey A; Scarborough RM; Lokker NA; Yu JC; Irie J; Tsukuda E; Ide S; Oda S; Nomoto Y
J Med Chem; 2002 Jul; 45(14):3057-66. PubMed ID: 12086491
[TBL] [Abstract][Full Text] [Related]
8. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
9. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of N-aryl-N'-[2-phenyl-3-quinazoline(3H)-4-one] acylthiourea derivatives as anticonvulsants.
Misra VS; Pandey RN; Dua PR
Pol J Pharmacol Pharm; 1979; 31(2):161-7. PubMed ID: 493181
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Palmer BD; Smaill JB; Boyd M; Boschelli DH; Doherty AM; Hamby JM; Khatana SS; Kramer JB; Kraker AJ; Panek RL; Lu GH; Dahring TK; Winters RT; Showalter HD; Denny WA
J Med Chem; 1998 Dec; 41(27):5457-65. PubMed ID: 9876115
[TBL] [Abstract][Full Text] [Related]
12. A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Hale JJ; Lynch CL; Neway W; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Parent SA; Chrebet G; Bergstrom J; Card D; Ferrer M; Hodder P; Strulovici B; Rosen H; Mandala S
J Med Chem; 2004 Dec; 47(27):6662-5. PubMed ID: 15615513
[TBL] [Abstract][Full Text] [Related]
13. Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.
Zhang P; Bao L; Fan J; Jia ZJ; Sinha U; Wong PW; Park G; Hutchaleelaha A; Scarborough RM; Zhu BY
Bioorg Med Chem Lett; 2009 Apr; 19(8):2186-9. PubMed ID: 19297158
[TBL] [Abstract][Full Text] [Related]
14. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
[TBL] [Abstract][Full Text] [Related]
15. 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Diaz G; Glaser KB; Guo J; Harris CM; Li J; Marcotte PA; Moskey MD; Oie T; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR
J Med Chem; 2008 Mar; 51(5):1231-41. PubMed ID: 18260617
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antiinflammatory screening of some quinazoline and quinazolyl-4-oxoquinazoline derivatives.
Gineinah MM; El-Sherbeny MA; Nasr MN; Maarouf AR
Arch Pharm (Weinheim); 2002; 335(11-12):556-62. PubMed ID: 12596220
[TBL] [Abstract][Full Text] [Related]
17. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
[TBL] [Abstract][Full Text] [Related]
18. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL
Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473
[TBL] [Abstract][Full Text] [Related]
19. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.
Kiesman WF; Zhao J; Conlon PR; Dowling JE; Petter RC; Lutterodt F; Jin X; Smits G; Fure M; Jayaraj A; Kim J; Sullivan G; Linden J
J Med Chem; 2006 Nov; 49(24):7119-31. PubMed ID: 17125264
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
